API reference
Trimetazidine
- CAS number
- 5011-34-7
- Molecular formula
- C14H22N2O3
- Molecular weight
- 266.34 g/mol
About this molecule
Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s. Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems. The increased intracellular calcium decreases contractility. It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate ischemic injury. However, evidence for this mechanism is controversial. Trimetazidine is not FDA approved. However, it has been approved in France since 1978.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
- InChIKey
- UHWVSEOVJBQKBE-UHFFFAOYSA-N
- SMILES
- COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC
- Other CAS numbers recorded
- 127881-54-3
- PubChem CID
- 21109
Also known as
Trimetazidina · Trimetazidinum · Dilatan · Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)- · 1-((2,3,4-trimethoxyphenyl)methyl)piperazine · Vastarel MR · C01EB15 · 225-690-2
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.